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atic literature review (May, 2015) to identify clinical trial evidence (i.e. randomized 
controlled trials, non-randomized controlled trials, and single-arm clinical trials) 
assessing sustained virological response rates among interferon-free and inter-
feron-containing antiviral regimens for hepatitis C. NMA require that the network 
is connected in order to facilitate adjusted indirect comparisons by which the 
treatment effect is isolated from the study effect. The study effects are estimated 
using common comparators. In the absence of common comparators, we incorpo-
rated the single-arm data directly into the Bayesian framework using simulated 
controls. The simulated controls were obtained by first modeling the reference 
treatment, and then using the constructed model to predict the most likely con-
trol outcome values given the observed trial characteristics. Using the simulated 
controls, traditional NMA methods were applied to the resulting data. Results: 
Seventy clinical trial arms, including 8,997 patients, contributed to the analysis of 
sustained virological response (SVR). All interferon-free regimens were statistically 
advantageous when compared to peginterferon-ribavirin (RR> 2.00). Furthermore, 
all interferon-free regimens were statistically better than telaprevir+peginterferon-
ribavirin, boceprevir+peginterferon-ribavirin, simeprevir+peginterferon-ribavirin, 
and sofosbuvir+ribavirin (RR> 1.25). No statistical differences were observed 
between the interferon-free regimens. Given the large disparity between the two 
treatment classes, use of simulated-control NMA did not lead to large differences 
in conclusions when compared to the naïve approach; however, the magnitude of 
estimates and rankings were affected. ConClusions: The use of single-arm tri-
als to assess interferon-free antivirals is common. We have shown that advanced 
statistical modeling can be used to assess the comparative efficacy new interferon-
free antiviral regimens.
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DaclatasvIr +asuNaPrevIr versus sofosbuvIr/leDIPasvIr for the 
treatmeNt of chroNIc hePatItIs c GeNotyPe 1 IN JaPaNese PatIeNts: a 
matchING-aDJusteD INDIrect comParIsoN
Swallow E1, Kelley C1, Ristovska L1, Signorovitch JE1, Kalsekar A2, Wygant G2, McPhee F2
1Analysis Group, Inc., Boston, MA, USA, 2Bristol-Myers Squibb Pharmaceuticals Ltd, Princeton, 
NJ, USA
objeCtives: To compare daclatasvir and asunaprevir (DCV+ASV) versus sofosbuvir/
ledipasvir (SOF/LDV) for HCV genotype 1b in Japanese patients without nonstruc-
tural protein 5A (NS5A) polymorphisms. Methods: Individual patient data were 
available from the two Phase 3 trials of DCV+ASV conducted in Japan (BMS 026/031); 
published summary data were extracted from the one Phase 3 trial of SOF/LDV con-
ducted in Japan (Mizokami et al.). Patients treated with DCV+ASV without baseline 
NS5A polymorphisms at L31F/I/M/V or Y93H were included in the present analysis 
and were subject to the enrollment criteria reported in the SOF/LDV trial. To adjust 
for cross-trial differences, patients in the DCV+ASV trial were weighted to match 
reported summary baseline characteristics: age, BMI, gender, prior treatment experi-
ence, prior treatment response, interferon eligibility, HCV RNA level, IL28B genotype, 
cirrhosis status, alanine aminotransferase, albumin, and platelets. Sustained viro-
logic response at week 12 post-treatment (SVR12) and discontinuation due to adverse 
events (AEs) were compared between the treatments. Results: Of the 363 patients 
treated with DCV+ASV, 282 had no baseline NS5A polymorphisms. Of these, 252 met 
the inclusion criteria of the SOF/LDV trial (n= 171) and were included in the analy-
sis. Prior to adjustment, the rate of SVR12 was lower among patients treated with 
DCV+ASV than SOF/LDV (95.2% vs. 100%; p= 0.004) and the rate of discontinuation 
due to AEs was higher among patients treated with DCV+ASV than SOF/LDV 
(4.8% vs. 0.0%; p= 0.004). After adjustment, both the rate of SVR12 and discontinu-
ation due to AEs were similar between patients treated with DCV+ASV and SOF/
LDV (SVR12: 99.3% vs. 100%; p= 0.398; discontinuation due to AEs: 1.3% vs. 0.0%; 
p= 0.327). ConClusions: After adjustment for cross-trial differences in baseline 
characteristics, DCV+ASV and SOF/LDV were associated with similar efficacy and 
discontinuation due to AEs in the treatment of HCV genotype 1b in Japanese patients 
without NS5A polymorphisms at L31F/I/M/V or Y93H.
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ProbIotIcs sIGNIfIcaNtly reDuce mortalIty IN Preterm  
NewborNs wIth NecrotIsING eNterocolItIs: results of larGe 
Network meta-aNalysIs
Aggarwal S1, Topaloglu H1, Kumar S2
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, 
USA
objeCtives: Several randomized control clinical trials have shown that Probiotics 
lower the death rates of preterm newborns with necrotising enterocolitis. However, 
most clinical guidelines do not currently support use of Probiotics. The objective 
of this study was to conduct a meta-analysis of mortality data from all available 
randomized control trials for Probiotics. Methods: A systematic literature search 
for randomized clinical trials for use of Probiotics in preterm newborns with necro-
tising enterocolitis (NEC) was undertaken for the databases Pubmed, Embase, Biosis, 
Google Scholar and Cochrane. Data was collected for the study type, methods, coun-
try and key findings. Extracted study data included study design, patient charat-
certristcis and NEC related outcomes. A random effects meta-analysis model was 
developed to estimate overall odds ratios and risk ratio. A bayesian random effects 
network meta-analysis model with vague and informative priors was also devel-
oped. Results: We identified 350 references and found 23 randomized trials in 7136 
newborns with 408 events. The mean size of the clinical trials was approximately 
300 patients. In the Probiotics and Placebo groups, there were 166 and 242 deaths, 
respectively. The random effects Odds Ratio for mortality for Probiotics versus 
Placebo was 0.69 (95% confidence interval 0.56 and 0.86; P= 0.0007). The random 
effects risk ratio for mortality for Probiotics versus Placebo was 0.72 (95% confidence 
interval 0.60 and 0.88; P= 0.00010). ConClusions: This large meta-analysis shows 
that use of Probiotics significantly reduces the risk and odds of death in preterm 
newborns with necrotising enterocolitis. There is an urgent need for updating clini-
cal guidelines based on this cumulative evidence.
general population controls. Results: In total, 49 026 patients with a HCV diag-
nosis were identified, of which 34 633 CHC patients were still alive and in Sweden 
on December 31st 2013 resulting in a CHC prevalence of 0.36% in 2013 (in males: 
0.46%; in females: 0.26%). Mean age in 2013 was 49 years (SD 12.95). Chronic liver 
disease and complications or symptoms of liver disease (including varices, ascites, 
liver cirrhosis, liver cancer and liver transplantation) were diagnosed and regis-
tered in 11% of CHC patients. Overall, 14.4% of all CHC patients had a co-infection 
with hepatitis B or HIV compared with 0.3% in the matched general population 
controls. The prevalence of psychiatric disorder, vascular, circulatory, and meta-
bolic disease were significantly higher in CHC patients compared with the general 
population controls. ConClusions: Our CHC prevalence was lower than previously 
reported. Patients with CHC had notably increased risk of other diseases compared 
to matched general population controls.
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outcome research to INvestIGate the actual status of mrsa 
INfectIoN aND usaGe of aNtI-mrsa DruGs IN real clINIcal settINGs IN 
JaPaN : a retrosPectIve Database stuDy
Yuasa A1, Ii Y1, Yamamoto Y2, Kitazaki S2, Saito K1, Fujimoto Y1
1Pfizer Japan Inc, Tokyo, Japan, 2MinaCare co.ltd, Tokyo, Japan
objeCtives: To provide real-world evidence from a Japanese healthcare database 
on the status of MRSA infections and the usage of anti-MRSA drugs in actual 
clinical settings. The overall medical treatment of MRSA patients was also inves-
tigated. Methods: This was a retrospective study based on claims data from 
a Japanese healthcare database composed of annual health check and claims 
from approximately 2.3 million members of employment-based health insurance 
groups and their dependents. The data of patients who had at least one record of 
being diagnosed with an MRSA infection (U80.1 in ICD-10/v2010) and being pre-
scribed anti-MRSA drugs approved in Japan were extracted from the 2014 database. 
An adult patient was defined as 15 years of age or older. Results: We identified 
patients (35.6% female, 77.7% adult) with an infection episode matching our defi-
nition. Among the 484 infection episodes, the top 3 infections were bacteremia 
(34.9%), pneumonia (19.6%), and surgical site infections (SSI) (7.2%). The site of 
infection was unknown in 29.8% of the patients. During the first month of the 
episode, Vancomycin, Teicoplanin, and Linezolid were prescribed in 72.9%, 16.9%, 
and 12.2% of patients, respectively. Compliance with the recommendations (drugs 
in A-I/A-II categories) of the latest Japanese MRSA treatment guidelines was fol-
lowed in 77.3%, 93.8%, and 89.7% of adult patients with bacteremia, pneumonia, 
and SSI, respectively. Blood culture tests were conducted in 54.7%, 37.0%, and 
27.6% of the adult episodes of bacteremia, pneumonia, and SSI. ConClusions: 
This is the first investigation to look at the actual status of MRSA infection using 
insurance claims data. It was found that the compliance with the Japanese MRSA 
treatment guidelines were generally high. However, utilization rate of blood culture 
test was low, even for the bacteremia patients. Further investigation is needed 
to determine the reason for this in order to ensure accurate diagnosis of MRSA 
infections in the future.
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coPING wIth DIscrePaNcIes IN ePIDemIoloGIcal Data from varIous 
sources for low-INcIDeNce DIseases: the case of multIDruG-
resIstaNt tuberculosIs IN GermaNy
Yates N, Leisten M, Huschens S, Wirth D
Janssen-Cilag GmbH, Neuss, Germany
objeCtives: Multidrug-resistant tuberculosis (MDR-TB) is designated an orphan 
disease in Germany, with less than 100 patients per year. TB case reporting has 
been obligatory since 2001 due to the Protection against Infection act (IfSG). The 
objective of this study was to compare the incidence of MDR-TB from different 
epidemiological data sources in Germany with data collected by the Robert-Koch-
Institute (RKI) according to the legal requirement. Methods: The following poten-
tial sources of epidemiological data of MDR-TB in Germany (for the year 2012) were 
searched: a systematic review of the literature, data from a statutory sickness fund 
(SHI) and data from the Federal Office of Administration (BVA) used for the risk 
adjustment scheme (Morbi-RSA) in the social health insurance system. Data from 
these sources were then compared with those collected by the RKI. Results: The 
systematic literature review provided 445 relevant abstracts which were screened 
by two independent reviewers. Selection of 16 possible full text papers revealed no 
relevant publications on MDR-TB in Germany. Data from sickness funds as well 
as the BVA also showed no reported cases of MDR-TB, although both gave indica-
tions on the incidence of drug-sensitive TB (91 cases/100,000 & 52 cases/100,000, 
respectively). The data provided by the RKI reported 4,187 cases of TB (incidence: 
5.2 cases/100,000) of which 65 cases (2.3%) were MDR-TB. ConClusions: Two 
factors are most striking: reports specific to MDR-TB are generally hard to find in 
SHI databases due to a lack of specific ICD-10 codes, but can be approximated with 
ICD-10 codes for drug-sensitive TB plus medication use. Furthermore, informa-
tion on TB incidence differs widely among the various data sources in Germany, 
possibly due to the different ways in which data are collected.
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the use of sINGle-arm evIDeNce IN the comParatIve effIcacy of 
INterferoN-free aNtIvIrals for treatmeNt-Naïve hePatItIs c 
GeNotyPe 1
Druyts E1, Kanters S2, Toor K1, Thorlund K2, Mills EJ3
1University of British Columbia, Vancouver, BC, Canada, 2Redwood Outcomes, Vancouver, BC, 
Canada, 3Stanford University, Stanford, CA, USA
objeCtives: Single-arm trials have played a major role in assessing the efficacy 
of interferon-free antiviral regimens for hepatitis C genotype 1. To facilitate evi-
dence synthesis, we have devised methods to integrate single-arm evidence into 
the network meta-analysis (NMA) framework to indirectly compare interferon-free 
and interferon-containing antiviral regimens. Methods: We conducted a system-
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Model calibration yielded R0= 1.1. A coverage of 50 to 75% of the 2-17 years-old with 
QLAIV averted 295,400 to 374,000 symptomatic influenza cases/year (-45% to -57% 
of the current number of cases), of which 187,000 to 242,000 cases were among 
adults ≥ 18 (due to indirect effects). Vaccinating 75% of the 2-11 years-old and 50% 
of the 12-17 years-old averted 333,200 cases/year (of which 213,000 cases/year were 
in adults). Vaccinating only healthy 2-5 years-old or only increasing the coverage of 
at-risk 2-17 children generated direct protection but only limited indirect protec-
tion even with 90% coverage: respectively 72,500 (-11%) or 37,500 (-6%) total averted 
cases/year. Sensitivity analyses showed robustness of these results. ConClusions: 
The model demonstrates both direct and indirect protection benefits of vaccinating 
healthy children with QLAIV in Belgium. Policies targeting only at-risk individuals or 
the youngest provide limited herd protection as school-age children are important 
influenza vectors due to their high contact frequencies within the community.
PIN10
aPProPrIateNess score aND cost evaluatIoN IN hIv: the aProsce 
system, oN fIelD clINIcal evaluatIoN
Gaggero D1, Marra D1, Giacomini M2, Giannini B2, Fraguglia C1, Cenderello G1, Cassola G1
1EO Ospedali Galliera, Genoa, Italy, 2Genoa University, genoa, Italy
objeCtives: The Highly Active Antiretroviral Treatment(HAART) expense plays 
a crucial role in managing resources properly .Aim of this work is to validate a 
scoring system that combines appropriateness, drug-spending and clinical out-
comes. Methods: All patients followed by our HIV outpatients service who started 
a first or an early switch regimen(II line) in 2014 have been enrolled. Demographic 
and epidemiological data were recorded. Each HIV treatment receives a score result-
ing from combining its relevance (according to Italian guidelines) and its related 
monthly cost. The most appropriate and less expensive regimen got a score of 1 
point, whilst other are rated declining progressively by 0,05 points according to their 
value based on the two parameters described above (range: 1-0,1). Furthermore, 
we followed the clinical course recording CD4 cell increase and HIV viral load 
decrease as a surrogate marker of quality of life. Results: 42 pts. included (29 
male); mean age : 42 years. 26 patients were in first line, 13 on early switch, 3 in 
both lines. Average treatment duration was 198 days (16-362). Mean CD4 was 270 
cc/ml for 1st line patients and 462 for early switch respectively. 11 Only 9 patients 
were classified C according to CDC criteria (A= 11; B= 26). We obtained an overall 
appropriateness score of 0,89, tenofovir-Based Single Tablet Regimens (TVD-STR) 
rated 0,99 , PI-Based Regimens got a score of 0,91. Mean monthly therapy cost was 
€ 627,3 vs. € 719,8 respectively. After three months, all patients were virologically 
suppressed. ConClusions: Our study helped in defining the APROSCE system as 
an efficacious tool to evaluate the correlation of treatment appropriateness, drug 
expense and clinical outcomes .Higher score is a predictor of better outcomes and 
less drug expenditure. Related savings might be invested in more complex patients 
management with multi drug resistant strains or AIDS presenter.
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estImatIoN of the relatIve effIcacy of lIceNseD reGImeNs for 
GeNotyPe-1 hcv INfectIoN usING a mIxeD treatmeNt comParIsoN
Gray E1, Leahy J2, O’Leary A3, Norris S4, Walsh C5
1School of Medicine, Trinity College Dublin, Dublin, Ireland, 2Department of Statistics, Dublin, 
Ireland, 3Royal College of Surgeons in Ireland, Dublin, Ireland, 4St James Hospital, Dublin, Ireland, 
5University of Limerick, Limerick, Ireland
objeCtives: A number of treatment combinations are licensed for genotype 1 (GT1) 
hepatitis C (HCV)infection. A mixed treatment comparison (MTC) is a methodological 
tool that allows estimation of the relative effectiveness of interventions that have not 
been compared directly through phase III comparative randomised controlled trials 
(RCT). The aim of this study is to indirectly estimate the relative treatment effect of 
licensed regimens for the treatment of genotype-1, treatment naïve (TN) patients with 
chronic HCV infection. Methods: A systematic review identified relevant phase II and 
III studies. Studies that evaluated licensed interferon-containing and interferon-free 
regimens for GT1 chronic HCV were included. A MTC was undertaken for an overall 
cohort of GT1, TN patients, not stratified according to genotype 1a or 1b, or the pres-
ence or absence of cirrhosis. Results were obtained by using Markov chain Monte 
Carlo simulation in OpenBugs3.2.3. Results: Two hundred and forty nine studies 
were identified of whom thirty-five met the inclusion criteria. Eight treatments were 
compared in a MTC analysis, where single-agent studies were excluded. A cumula-
tive rankogram was constructed which illustrated that the probability of sofosbuvir/
daclatasvir (SOF/DCV) being the most effective treatment was 55%. This was fol-
lowed by sofosbuvir/ledipasvir (SOF/LDV) (37%) and paritaprevir, boosted with rito-
navir, in combination with ombitasvir and dasabuvir with ribavirin (P/rOD) (6.6%). 
Incorporating additional evidence from single-agent studies and matching them with 
data from similar arms of other studies allows for the inclusion of two additional regi-
mens; daclatasvir with pegylated-interferon and ribavirin (DCV/PR) and simeprevir/
sofosbuvir (SIM/SOF). ConClusions: In this MTC, SOF/DCV is the most effective 
treatment for genotype 1, TN hepatitis C patients. In the absence of head-to-head 
trials, MTCs play a crucial role in guiding clinical decision making. The analysis from 
this study will provide relevant information on licensed regimens for the hepatitis C 
infected, genotype 1, treatment naïve patients.
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systematIc lIterature revIew (slr) aND Network meta-aNalysIs 
(Nma) of teNofovIr/emtrIcItabINe (tDf/ftc) aND abacavIr/lamIvuDINe 
(abc/3tc) backboNe reGImeNs for hIv-1
Agirrezabal I1, LeReun C2, Eddowes LA1, Kusel J1, Perard R3
1Costello Medical Consulting Ltd, Cambridge, UK, 2Independent Biostatistician, Sainte-Anne, 
Guadeloupe, 3Gilead Sciences Europe Ltd, Uxbridge, UK
objeCtives: Recommended treatment regimens for HIV-1-infected patients com-
bine antivirals from different therapeutic classes, usually a two-drug backbone (TDF/
FTC or ABC/3TC) with a third agent from another therapeutic class. We sought to 
understand the clinical evidence differentiating these backbones in treatment-naïve 
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loNG term vIroloGIcal outcomes of hIv INfecteD PatIeNts oN 
aNtIretrovIral treatmeNt IN uGaNDa
Castelnuovo B, Kiragga A, Mubiru F, Kambugu A, Reynolds S
Infectious Diseases Institute, Kampala, Uganda
objeCtives: To evaluate the virological outcomes of a cohort of HIV infected 
patients started on antiretroviral treatment (ART) and followed up for 10 years in 
Uganda. Methods: The study was performed at the Infectious Diseases Institute, 
Uganda. Viral load (VL) testing was performed every 6 months. We reported propor-
tion and cumulative probability (Kaplan Meier methods) of 1) achieving viral sup-
pression (VS) (at least one VL < 400 copies/ml) 2) experiencing viral failure in patients 
who achieved suppression, (2 consecutive VL > 1000 copies or one VL> 5,000 for those 
without a subsequent VL according to WHO guidelines) We used Cox regression 
methods to determine the characteristics associated with unfavorable virological 
outcomes (no suppression or viral failure). We included gender, baseline age, WHO-
stage, body max index (BMI), CD4 count, VL and time-dependent CD4-count and 
ART-adherence. Predictors with a P-value ≤ 0.2 in the unadjusted analysis were 
included in the multivariate analysis. Results: 472/559 (84.8%) patients had at 
least one VL (67 died, 14 lost, 4 transferred, 2 no VL available). 69% were female, 
median age was 44 years (IQR: 39-51), 89.9% were in WHO-stage 3&4, median CD4 
count was 102 cell/µL (IQR:31-167), median log10 VL 5.4 (IQR:5.1-5.8); 73.6% started 
on d4T/3TC/nevirapine and 26.4% on AZT/3TC/efavirenz. 439/472 (93%) achieved VS, 
cumulative probability: 94.1% (CI:91.7-96.1). 135/439 (30.7%) experienced VF, cumula-
tive probability: 33.9 %(CI: 29.4-38.9). In the multivariate analysis initial d4T/3TC/
nevirapine (HR:1.92, CI:1.28-2.87, P< 0.001) was associated with unfavorable viral 
outcomes while patients with adherence > 95% (HR:0.12, CI:0.05-0.27) and higher 
time-dependent CD4-count (HR:0.993 per 50 cell/µL increase, CI:0.94-0.99, P< 0.001) 
were less likely to obtain an unfavorable outcome. ConClusions: Achieving and 
maintaining viral suppression is associated with reduction in mortality and mor-
bidity and it is a key factor in the strategy of using ART as treatment as prevention: 
our results are encouraging and comparable to those from resource-rich settings.
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aDhereNce, healthcare resource use (hru) aND costs: a comParIsoN 
of sINGle-tablet reGImeN (str) versus multI-tablet reGImeN (mtr) 
coNtaINING fIxeD Dose combINatIoN (fDc) reGImeNs
Narayanan S1, Clay PG2
1Ipsos Healthcare, Washington, DC, USA, 2University of North Texas System College of Pharmacy, 
Fort Worth, TX, USA
objeCtives: A comparison of all available once-daily fixed dose STR to MTR (of 
any frequency, containing FDC) using randomized controlled trials, observational 
studies and economic models focused on adherence measures could inform HIV 
healthcare providers and policy makers regarding modalities of patient disease man-
agement to improve health outcomes. A systematic review and meta-analysis of 
published literature was conducted to compare STR to MTR. Methods: Published 
literature in English between 2005 and 2014 was searched using Embase, Medline, 
PubMed (Medline in-process) and ClinicalTrial.Gov databases. Two-level screening 
was undertaken by two independent researchers to finalize articles for evidence 
synthesis. Adherence, efficacy, safety, tolerability, HRU and costs were assessed 
comparing STR to MTR. A random effects meta-analysis was performed and 
heterogeneity examined using meta-regression. Adherence, HRU/Cost evaluations 
are summarized in this abstract. Results: Of the 39 articles identified for qualitative 
evidence synthesis, 22 reported patient adherence outcomes and 5 had quantifiable 
data for meta-analysis. STR patients were statistically significantly more adher-
ent (per respective study-defined adherence goals) compared to MTR patients of 
any frequency (Odds Ratio (OR):2.37 (95% CI:1.68, 3.35) (p < 0.001)), twice-daily MTR 
(OR:2.53 (95% CI:1.13, 5.66) and once-daily MTR (OR:1.81 (1.15, 2.84)). Several stud-
ies reported significant reduction in HRU and costs among STR group versus MTR 
(albeit, none was eligible for meta-analysis): mean costs (annual, bi-annual, monthly 
or per-diem) were found to be lower for the STR group compared to MTR, and STR was 
also deemed cost-effective, based on its lower incremental cost-effectiveness ratio 
(ICER). ConClusions: STR demonstrated significant impact on improving adherence 
and potentially lowering overall HRU and costs in comparison to MTR. These find-
ings may have policy implications for HIV disease management in resource-limited 
settings, considering the known associations between ART adherence and improve-
ments in humanistic/clinical burden among HIV patients, and the potential HRU/
cost savings associated with STRs.
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PublIc health outcomes of PaeDIatrIc INflueNza vaccINatIoN wIth 
aN INtraNasal tetravaleNt lIve atteNuateD vaccINe IN belGIum 
usING a DyNamIc traNsmIssIoN moDel
Gerlier L1, Lamotte M1, Dos Santos Mendes S2, Schwehm M3, Eichner M4
1IMS Health, Vilvoorde, Belgium, 2AstraZeneca Belux, Uccle, Belgium, 3ExploSYS GmbH, 
Leinfelden-Echterdingen, Germany, 4Epimos GmbH, Dusslingen, Germany
objeCtives: To estimate the public health outcomes associated with vaccination of 
healthy Belgian children aged 2-17 years using an intranasal tetravalent live-attenu-
ated influenza vaccine (QLAIV), compared to the current coverage of at-risk/elderly 
individuals with the trivalent inactivated vaccine (TIV). Methods: A deterministic, 
age-structured, dynamic model was used to simulate influenza transmission (4 
strains) in the Belgian population, under the current coverage or after extending 
vaccination coverage to healthy children aged 2-17 with QLAIV. Differential equa-
tions describe demographic changes, exposure to infectious individuals (between-
individuals contact frequencies from the Belgian POLYMOD matrix), vaccination 
immunity dynamics, infection and recovery (parameters from international lit-
erature). The basic reproduction number (R0) was calibrated to the observation of 
285,951 influenza doctor visits/year (Belgian surveillance network). Efficacy was 
80% QLAIV vs. 59-68% TIV. The 10-year incidence of symptomatic influenza was 
calculated with different coverage scenarios (add-on to current coverage). Results: 
